↓ Skip to main content

The Survival Benefit for Optimal Glycemic Control in Advanced Non-Small Cell Lung Cancer Patients With Preexisting Diabetes Mellitus

Overview of attention for article published in Frontiers in oncology, November 2021
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Good Attention Score compared to outputs of the same age and source (78th percentile)

Mentioned by

twitter
3 X users

Citations

dimensions_citation
2 Dimensions

Readers on

mendeley
7 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
The Survival Benefit for Optimal Glycemic Control in Advanced Non-Small Cell Lung Cancer Patients With Preexisting Diabetes Mellitus
Published in
Frontiers in oncology, November 2021
DOI 10.3389/fonc.2021.745150
Pubmed ID
Authors

Jie Qian, Weimin Wang, Lin Wang, Jun Lu, Lele Zhang, Bo Zhang, Shuyuan Wang, Wei Nie, Yanwei Zhang, Yuqing Lou, Baohui Han

X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 7 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 7 100%

Demographic breakdown

Readers by professional status Count As %
Lecturer 1 14%
Other 1 14%
Student > Doctoral Student 1 14%
Unknown 4 57%
Readers by discipline Count As %
Nursing and Health Professions 2 29%
Unknown 5 71%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 April 2024.
All research outputs
#16,438,130
of 26,390,482 outputs
Outputs from Frontiers in oncology
#5,269
of 23,081 outputs
Outputs of similar age
#213,878
of 420,109 outputs
Outputs of similar age from Frontiers in oncology
#267
of 1,352 outputs
Altmetric has tracked 26,390,482 research outputs across all sources so far. This one is in the 36th percentile – i.e., 36% of other outputs scored the same or lower than it.
So far Altmetric has tracked 23,081 research outputs from this source. They receive a mean Attention Score of 3.2. This one has gotten more attention than average, scoring higher than 74% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 420,109 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 47th percentile – i.e., 47% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 1,352 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 78% of its contemporaries.